[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrent-utis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrent-utis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100585809","phase-1-daily-nitrofurantoin-versus-bladder-fulguration-plus-daily-nitrofurantoin-for-women-with-recurrent-urinary-tract-infections-100585809",false,"NCT06907199","Daily Nitrofurantoin Versus Bladder Fulguration Plus Daily Nitrofurantoin for Women With Recurrent Urinary Tract Infections","A Multicentric Randomized Trial of Daily Nitrofurantoin Versus Bladder Fulguration Plus Daily Nitrofurantoin for the Long-term Management of Cystitis in Women With Recurrent Urinary Tract Infections","Inclusion Criteria:\n\n* Females 18 to 85 years old with at least a 1-year history of culture documented uncomplicated rUTI.\n* Diagnosis of rUTI, defined as ≥ 3 symptomatic UTIs in 12 months or ≥ 2 in 6 months.\n* Currently free from a UTI determined based on absence of symptoms as determined by the UTI symptom assessment questionnaire and negative urine culture (\\\u003C10\\^3 colony forming units per ml of urine).\n* A negative upper and lower urinary tract evaluation, including pelvic examination for pelvic organ prolapse (less than or equal to stage 2), measurement of post-void residual (less than 50 ml), and imaging (which may include renal ultrasound and standing voiding cystourethrogram) to exclude kidney stone, hydronephrosis, reflux, or urethral diverticulum.\n* Office cystoscopy documenting stages 1 or 2 of chronic cystitis.\n* Likely to stay in the geographic region for the duration of the study.\n* ASA class II or less.\n\nExclusion Criteria:\n\n* Patients on antibiotics at baseline (i.e., suppressive therapy or antibiotic therapy for non-urinary infections).\n* Patients on self-start therapy (i.e., taking antibiotics upon start of urinary symptoms concerning for UTI).\n* Patients on prophylactic antibiotics started in the last 3 months and unwilling to discontinue, or intention to start in the next 12 months.\n* Complicated UTIs, including neurogenic bladder condition (i.e., multiple sclerosis, Parkinson's disease, spinal cord injury), bladder augmentation, or urinary diversion.\n* Patients with urinary catheters (including indwelling Foley, intermittent catheterization, and suprapubic catheters).\n* Uncontrolled diabetes (HbA1c \\>9).\n* Pregnancy\n* Allergy or resistance to Nitrofurantoin.\n* Chronic lung or liver condition precluding the use of Nitrofurantoin, including abnormal chest X ray or elevated liver function tests.\n* Chronic renal insufficiency (creatinine over 1.5 g\u002Fdl or GFR less than 40) precluding the use of Nitrofurantoin.\n* History of chronic diarrhea requiring regular therapy.\n* Patients with psychosis, dementia, swallowing disorders, or any other ability to take Nitrofurantoin reliably at home.\n* BMI over 40.\n* Use of Uromune or other vaccine approaches to reduce rUTI episodes\n* Participation in a research study involving an investigational product in the past 12 weeks.\n* Patients receiving phage therapy.\n* Current diagnosis of interstitial cystitis.\n* Patients with medical conditions requiring excessively large amounts of fluid intake.","FEMALE","18 Years","85 Years",{"count":20,"type":21},104,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The goal of this clinical trial is to learn if the drug Nitrofurantoin (NF) taken as a daily antibiotic, works to treat cystitis compared to electrofulguration (EF) and Nitrofurantoin (NF) daily antibiotic.",[27,28],"Recurrent UTIs","Cystitis Recurrent",[30,31,32,33,34],"bladder fulguration","Nitrofurantoin","long-term managenent of cystitis","Recurrent UTI","chronic UTI","RECRUITING","2026-04-27",{"date":38,"type":39},"2026-05-01","ACTUAL",{"date":41,"type":39},"2026-04-06",{"date":43,"type":21},"2029-01-30",{"name":45,"class":46},"University of Texas Southwestern Medical Center","OTHER",2,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100610949","phase-1-genitourinary-study-of-fostering-lactobacillus-to-optimize-the-microbiome-in-womens-health-gud-flora-100610949","NCT07234227","Genitourinary Study of Fostering Lactobacillus to Optimize the Microbiome in Women's Health (GUD-FLORA)","GUD-FLORA","Inclusion Criteria\n\n* English-speaking\n* ≥ 18 years of age\n* Diagnosed with recurrent urinary tract infections (UTIs). Specifically, participants will have had 3 UTIs over the past 12 months or 2 UTIs over the past 6 months. At least one of these UTIs must be culture-proven. For UTIs to count for this study, if not culture-proven they must involve the onset of UTI-related symptoms (dysuria, urgency, frequency, suprapubic pain, or urinary changes, etc) with prescription of antibiotics directed at UTI treatment.\n\nExclusion Criteria\n\n* Chronically self-catheterize.\n* Currently use of a vaginal pessary.\n* Have used a vaginal probiotic in the prior 3 months.\n* Are pregnant or within 1 year postpartum.\n* Have poorly controlled diabetes with an A1c of 9 or greater.\n* Are considered immunocompromised\n* Are unable to personally provide legal consent",{"count":56,"type":21},156,[24],"The objective of this study is to evaluate the use of a vaginal probiotic in patients with recurrent urinary tract infections (UTIs). Specifically, this study aims to evaluate factors associated with successful colonization with Lactobacillus crispatus - a known \"healthy\" and protective bacteria in both the vaginal and urinary microenvironments. The study will recruit patients over age 18 with a clinical diagnosis of recurrent UTIs, and will utilize a commercially available Lactobacillus vaginal probiotic. Participants will use the probiotic product with the commercially approved packaging and regimen for a total of 3 months. Vaginal and urinary samples will be obtained at four different timepoints. Participants will also be asked to complete surveys regarding tolerability and acceptability of the probiotic product. Patient samples will be analyzed in the laboratory to understand the effects of the probiotic on the local microbiome. Survey data and demographic information will be housed within the Research Electronic Data Capture (RedCap) secure server. For our primary analysis, Lactobacillus crispatus (L. crispatus) abundance will be measured and used as the outcome variable in a linear regression model evaluating the impact of baseline patient and microbiome characteristics on L. crispatus colonization.",[27],[33,61,62,63,64,65],"Microbiome","Probiotic","Vaginal probiotic","Lactobacillus","Urinary tract infection","NOT_YET_RECRUITING","2026-01-26",{"date":69,"type":39},"2026-01-28",{"date":71,"type":21},"2026-06",{"date":73,"type":21},"2028-02",{"name":75,"class":46},"Duke University",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":18,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":89,"conditions":90,"keywords":98,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},"100588378","a-trial-of-d-mannose-for-the-prophylaxis-of-recurrent-urinary-tract-infections-100588378","NCT06940622","A Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections","A Randomized Controlled Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections in Post-menopausal Women","DmannoseRCT","Inclusion Criteria:\n\n* Female, post-menopausal, age ≥ 55 years old\n* Diagnosis of recurrent UTI, defined as ≥ 3 symptomatic culture-proven UTI episodes in 12 months or ≥ 2 in 6 months.\n* Currently free from a UTI determined based on absence of symptoms as determined by the UTI symptom assessment questionnaire79 and negative urine culture (\\\u003C103 colony forming units per ml of urine).\n* Able to attend all follow-up appointments for the study.\n* A negative upper and lower urinary tract evaluation, including pelvic examination for pelvic organ prolapse (less than stage 2), measurement of post-void residual (less than 50 ml), and imaging (renal ultrasound and standing voiding cystourethrogram) to exclude kidney stone, hydronephrosis, reflux, or urethral diverticulum.\n\nExclusion Criteria:\n\n* Current use of D-mannose. Patients willing to stop taking D-mannose will be offered to join the trial after a 4-week wash-out period.\n* Complicated UTIs, including need for catheter drainage or intermittent catheterization, neurogenic bladder, bladder augmentation, or urinary diversion.\n* Ongoing supplement use (Box 1). Patients willing to stop taking the listed supplements will be offered to join the trial after a 4-week wash-out period.\n* Evidence of upper tract infection (pyelonephritis), including temperature higher than 38°C, flank\u002Flumbar pain or tenderness\n* Diagnosis of interstitial cystitis or overactive bladder syndrome\n* Prophylactic antibiotics started in the last 3 months and unwilling to discontinue, or intention to start in the next 12 months\n* Use of Uromune or other vaccine approaches to reduce rUTI\n* Participation in a research study involving an investigational product in the past 12 weeks\n* Receipt of phage treatment\n* History of chronic diarrhea requiring regular therapy\n* Inability to swallow or known history of gastrointestinal malabsorption\n* History of recurrent vaginal yeast infections\n* Systemic disease precluding enrollment in this study (uncontrolled diabetes with HgA1C above 7, ongoing chemotherapy or immunotherapy, renal insufficiency \\[creatinine \\> 1.5 g\u002Fdl\\]), mental or cognitive impairment, weight loss diet requiring excessively large amounts of fluid intake, or other health-related specific diet).\n* Nursing home resident\n* BMI \\>40\n\nBox 1 Supplements to avoid\n\n* Multi-Vitamins and Multi-Mineral capsules\n* Specific Vitamins or Minerals (e.g., Calcium, Citrical, Calcium Gummies, Vitamin A, D, Niacin, Pyridoxine, Selenium, Vitamin E, B6, Iron, Omega 3, D3, Magnesium, B-Complex, Women's Ultra MultiVitamin, GNC B-Complex, B-12, PreserVision Areds2, Vitamins D, B Pollen)\n* Probiotics\n* Cranberry Mannose or Cranberry Extract Weight loss products to avoid\n* Medifast\n* Vitafusion\n* OptiVin Products\n* Appetite Suppressants\n* Keto-Fuel","55 Years",{"count":86,"type":21},90,[88],"NA","A randomized, double-blind, placebo-controlled, 12-month study to determine the effectiveness of D-mannose (2g daily) supplementation in rUTI (recurrent urinary tract infection) prevention in post-menopausal women.",[27,91,92,93,28,94,95,96,97],"Recurrent Urinary Tract Infections","Recurrent Urinary Tract Infections in Women","Recurrent Urinary Tract Infection","Cystitis Chronic","UTI","UTI - Urinary Tract Infection","UTI - Lower Urinary Tract Infection",[99,100,101,102,103,104,105,106,107],"D-mannose","dmannose","uti","ruti","recurrent urinary tract infection","urinary tract infection","cystitis","chronic uti","chronic cystitis","2025-09-18",{"date":110,"type":39},"2025-09-22",{"date":112,"type":39},"2025-08-01",{"date":114,"type":21},"2030-09-30",{"name":45,"class":46},1]